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Abstract
Background: Micro(mi)RNAs are a class of small non-coding RNAs that play critical roles in the induction of various 
cancers, including lymphomas induced by oncogenic viruses. While some of the miRNAs are oncogenic, miRNAs such 
as miR-26a are consistently downregulated in a number of cancers, demonstrating their potential tumor suppressor 
functions. Global miRNA expression profiles of a number of virus-transformed avian lymphoma cell lines have shown 
downregulation of gga-miR-26a expression, irrespective of molecular mechanisms of transformation or the viral 
aetiology. The neoplastic transformation of lymphocytes by many viruses accompanies high levels of proliferative 
responses, mostly mediated through cytokines such as IL-2. Chicken IL-2 can modulate T-cell proliferation and 
cytotoxicity in vitro and in vivo and dysregulation of IL-2 expression is observed in diseases such as leukaemia.
Results: The expression levels of gga-miR-26a in chicken lymphoma cells transformed by 3 distinct avian oncogenic 
viruses, viz Marek's disease virus (MDV), avian leukosis virus (ALV) and Reticuloendotheliosis virus (REV) were 
consistently downregulated compared to the levels in the normal lymphocytes. This downregulation of miR-26a 
regardless of the viral etiology and molecular mechanisms of transformation was consistent with the tumor suppressor 
role of this miRNA. Notwithstanding this well-established role in cancer, we demonstrate the additional role of this 
miRNA in directly targeting chicken IL-2 through reporter and biochemical assays. The downregulation of miR-26a can 
relieve the suppressive effect of this miRNA on IL-2 expression.
Conclusions: We show that miR-26a is globally downregulated in a number of avian lymphoma cells irrespective of 
the mechanisms of transformation, reiterating the highly conserved tumor suppressor function of this miRNA. 
However, with the potential for directly targeting chicken IL-2, the downregulation of miR-26a in these tumor cells 
could relieve the inhibitory effect on IL-2 expression assisting in the proliferative features of the transformed 
lymphocyte lines.
Background
Micro(mi)RNAs are a large class of ~22-nucleotide non-
coding RNA molecules that participate a major part in 
the regulation of gene expression in majority of the 
eukaryotes. Increasingly, they have been shown to play 
significant roles in a variety of cancers, in particular of 
those involving different blood cells [1]. Marek's disease 
(MD), a naturally occurring CD4+ T-cell lymphoma in 
chickens induced by Marek's disease virus (MDV), is con-
sidered to be a very good model for herpesvirus-induced 
rapid-onset T-cell lymphomas [2]. Recent studies on the 
miRNA expression profiles of a number of MDV-trans-
formed chicken lymphoid cell lines have shown signifi-
cant alterations in the expression of several host miRNAs 
compared to the normal chicken lymphocytes [3]. One of 
the miRNAs that was consistently downregulated in a 
number of MDV-transformed chicken lymphoid cell lines 
is gga-miR-26a [3]. Suppression of miR-26a has been 
demonstrated in a variety of human cancers also [4-6] 
suggesting that miR-26a has potential tumour suppres-
sion functions, and its downregulation could be essential 
for transformation. This notion is supported from the 
roles of miR-26a in p53 tumour suppressor network [7], 
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as well as in the regulation of transformation-related tar-
gets such as cyclin D2, SMAD1, EZH2 and PTEN [8,9].
Antigen-specific T cell proliferation and immunological 
responses are dependent on the expression of several 
cytokine genes such as interleukin-2 (IL-2). IL-2 plays an 
important role in the development, differentiation and 
homeostasis of T cells, and IL-2 expression is dysregu-
lated in diseases such as leukaemia, autoimmunity and 
pathogenesis of viral diseases [10], including MD [11]. As 
in mammals, the chicken IL-2 can modulate T-cell prolif-
eration and cytotoxicity in vitro and in vivo [12]. The 
mechanisms of transcriptional regulation of IL-2 promot-
ers through activating transcription factors such as NFκB 
or AP-1 have been extensively studied [13]. Negative reg-
ulation of IL-2 expression is also important both for 
maintaining the gene in an inactive state in resting cells 
and for repressing the gene after the activation. Com-
pared to the studies on transactivation, the mechanisms 
involved in the negative regulation of IL-2 gene expres-
sion are less well studied. Although the roles of co-repres-
sors and histone deacetylases in the transcriptional 
repression of IL-2 has been demonstrated [14], it is also 
becoming clear that a number of miRNAs are also 
involved in shaping of the immune responses [15,16] at 
least in part through the regulation of cytokine genes 
[17]. For example, miR-146a has been shown to modulate 
the adaptive immune responses by regulating the IL-2 
expression in human T lymphocytes [18]. However, 
chicken IL-2 is not a predicted target of gga-miR-146a 
http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/tar-
gets/. Although miR-26a has not been implicated in the 
regulation of IL-2, we examined whether miR-26a down-
regulation in MDV-transformed chicken lymphoma cell 
lines do affect IL-2 expression. We present the data sug-
gesting that chicken IL-2 is a direct target of miR-26a, 
and its downregulation could affect IL-2 expression and 
signalling pathways in these transformed cells.
Results
Transformed chicken cell lines show downregulation of 
miR-26a
Comparative miRNA expression profiles of 7 MDV-
transformed T-cell lines showed that host-encoded miR-
NAs such as miR-26a, miR-223, miR-150, miR-451 and 
miR-126 were consistently downregulated [3]. We have 
now extended the analysis to examine the levels of miR-
26a in four of the above MDV-transformed cell lines 
together with ALV-transformed cell line HP45 and REV-
transformed cell lines AVOL1 and AVOL2. The microar-
ray readouts of miRNA expression confirmed that the 
miR-26a levels in all of these cell lines were lower than the 
levels in normal splenocytes, although the levels of reduc-
tion varied between cell lines (Fig. 1a). Further validation 
of the reduced expression of miR-26a in these trans-
formed cells was demonstrated by Northern blotting 
analysis on RNA extracted from these cell lines together 
with normal CD4+, CD4- and unsorted splenocytes (Fig 
1b). The levels of miR-26a signal detected were very high 
in normal splenocytes, with no major differences 
between CD4+ and CD4- T cell populations. In contrast, 
the signals of miR-26a were very low in all transformed 
cell lines, including those transformed by ALV and REV. 
In some MD lymphoma lines (T226S, T265L & T273S), 
the miR-26a levels were undetectable.
Targeting of chicken IL-2 by miR-26a in reporter assays
To gain insights into the biological functions of miR-26a, 
we carried out bioinformatic analysis to identify potential 
targets of miR-26a by scanning the chicken 3' UTR 
sequences using the miRanda http://www.microRNA.org 
for potential targets of miR-26a. This analysis predicted 
that the 3' UTR of chicken IL-2 contained a binding site 
for miR-26a showing its potential as miR-26a target (Fig. 
2a). For further validation of targeting of chicken IL-2 by 
miR-26a, we constructed reporter vectors with wildtype 
(wt) or a mutant 3' UTR sequence of the chicken IL-2 
with three base-pair mutations in the predicted miRNA 
binding seed region (Mu) fused to the Renilla luciferase 
gene in psiCHECK-2 vector (Fig. 2a). Reporter assays on 
DF-1 cells that express endogenous miR-26a demon-
strated that the luciferase reporter levels in the cells 
transfected with the Wt-3' UTR reporter construct was 
reduced by nearly 35% (p < 0.05) compared to the Mu-3' 
UTR construct (Fig. 2b).
Figure 1 Downregulation of gga-miR-26a in transformed cell 
lines. Reduced expression of miR-26a in MDV (MSB-1, T226S, T265L 
and T273S), ALV (HP45) and REV (AVOL1 and AVOL2)-transformed cell 
lines. (a) Heat map of miR-26a expression in tumour cell lines com-
pared with the levels in splenocytes as the reference. Log2 values of in-
creased (red) and reduced (green) expression are shown. (b) Northern 
blot analysis of total RNA extracted from the above cell lines and un-
sorted splenocytes or sorted CD4+/CD4- cells with the anti-miR-26a 
probe showing differences in the miR-26a expression. U6 RNA was 
used as the control probe for loading control.Xu et al. Cancer Cell International 2010, 10:15
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Downregulation of IL-2 expression by miR-26a
As we did not have an antibody that specifically detected 
the chicken IL-2, we constructed vectors that expressed 
HA tagged-chicken IL-2 with either the wildtype 3' UTR 
sequence or with miR-26a binding site mutant sequence. 
Western blot analysis of the IL-2 expression levels with 
anti-HA antibody in DF-1 cells transfected with the Wt 
or the mu IL-2 expression constructs showed that the IL-
2 levels in constructs expressing the Wt 3' UTR was 
reduced by more than 20% compared to the Mu con-
structs (Fig 3), showing a direct silencing of IL-2 expres-
sion by miR-26a.
Levels of miR-26a affect IL-2 expression
For further evidence to show that IL-2 levels are regu-
lated by miR-26a, we performed experiment in which the 
miR-26a levels in DF-1 cells are either upregulated by 
overexpression or downregulated by specific silencing. 
For overexpression, we transfected DF-1 cells with the 
miR-26a expression construct pEF6-miR-26a (+). As the 
negative control, we used the construct pEF6-miR-26a (-
), in which the miRNA was cloned in the reverse orienta-
tion. Northern blot analysis of DF-1 cells transfected with 
the two vectors showed that the miR-26a expression level 
of pEF6-miR-26a (+) transfected cells was higher than 
that of normal DF-1 cells or the cells transfected with the 
pEF6-miR-26a (-) vector (Fig. 4a). For downregulation of 
miR-26a, anti-miR-26a construct was transfected into 
DF-1 cells. Northern blot showed that anti-miR-26a dra-
matically reduced miR-26a levels compared to negative 
control (Fig. 4b).
We also examined how the changes in the expression of 
miR-26a affected the IL-2 expression. MiR-26a expres-
sion vector and control vector were respectively co-trans-
fected with pcDNA-IL-2-3HA-3'UTR into DF-1, and 
then cells were examined by western blot analysis (Fig. 
4c). It showed that the IL-2 expression level was reduced 
by more than 30% in the presence of miR-26a compared 
to the levels in cells transfected with pEF6-miR-26a (-) 
control vector. In contrast, the IL-2 expression level was 
increased by more than 140% when the miR-26a levels 
were silenced using the anti-miR-26a compared to the 
anti-miRNA control (Fig.4d).
Discussion
Over the last 5 years, miRNAs have emerged as major 
regulators of gene expression and cancer pathogenesis. 
Figure 3 Western blot analysis of the IL-2 expression. DF-1 cells 
transfected with pcDNA-IL-2-3HA-3'UTR wild-type or mutant con-
structs were detected using anti-HA tag antibody. The levels of α-tubu-
lin in the cell lysates are also shown as the loading control.
Figure 2 Chicken IL-2 is a target for miR-26a. (a) Nucleotide sequences of the wild-type and mutant miR-26a binding sites (mutated residues un-
derlined) located in the 3' UTR of Gallus gallus IL-2 gene (NM_204153). (b) Reporter assays on DF-1 cells transfected with the reporter vectors contain-
ing either the wildtype or mutated IL-2 3' UTR. Reduction in the ratio of Renilla to Firefly luciferase levels (p < 0.05) in the wildtype construct to the 
normalised 100 per cent levels for the mutant construct is shown.
5’ GTCTGTTCTAAGATCATATTTGAT 3’ Wildtype IL-2
|:||:|:||  |||  ||:||||
3’ CGGAUAGGA-CCUA--AUGAACUU 5’ miR-26a
|:||:|:||  |||  || | | 
5’ GTCTGTTCTAAGATCATAGTAGTT 3’ Mutant IL-2
(b) (a)Xu et al. Cancer Cell International 2010, 10:15
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Nearly all of the tumours, irrespective of the cell type or 
etiology, have shown globally abnormal miRNA expres-
sion patterns and miRNA profiles of tumours have given 
valuable insights into downstream pathways of oncogene-
sis [19-25]. We have previously demonstrated that miR-
26a is downregulated in seven independently-derived 
MDV-transformed lymphoblastoid T cell lines [3]. Here, 
we show that such downregulation of miR-26a occur in 
lymphoid cell lines transformed by ALV and REV also, 
suggesting that miR-26a-mediated modulation of gene 
expression is probably crucial for lymphocyte transfor-
mation, irrespective of the viral etiology. The identifica-
tion of some of the validated targets of miR-26a including 
EZH2 [9], SMAD1 [26], PTEN [8] provides intriguing 
link to the oncogenic pathways. Loss of expression of 
miR-26a also occurs in some of the human tumours such 
as thyroid anaplastic carcinoma [6] and Burkitt's lym-
phoma [9] reiterating the role of miR-26a as a tumour 
suppressor, the expression of which can protect from the 
disease progression in cancer models [5,27].
In this study we demonstrate that, in addition to its 
potential role as a tumour suppressor, miR-26a also func-
tions as a modulator of IL-2 expression. IL-2 is produced 
mainly by activated T helper CD4+ lymphocytes and is 
one of critical cytokines that control the proliferation and 
clonal expansion of transformed lymphoma cells [28]. In 
MDV-transformed tumour cells, MDV-encoded onco-
protein Meq is thought to play a direct role in the upregu-
lation of IL-2 expression by binding to the IL-2 promoter 
[29]. Our study shows that the downregulation of miR-
26a is another global pathway for the increased IL-2 
expression in the lymphoma cell lines transformed by the 
avian oncogenic viruses MDV, ALV and REV.
Our study does not examine the molecular mechanisms 
of downregulation of miR-26a. Some of the previous 
studies have shown the role of oncogenes such as c-myc 
Figure 4 Regulation of chicken IL-2 expression by miR-26a in DF-1 cells. (a) Northern blot analysis of total RNA extracted from DF-1 cells trans-
fected with miR-26a expression or control vectors using anti-miR-26a probe. (b) Northern blot analysis demonstrating the specific silencing of miR-
26a expression with anti-miR-26a, but not with anti-miRNA control. U6 RNA was used as the control probe for loading control. (c) Western blot analysis 
of chicken IL-2 expression in DF-1 cells co-transfected with HA-tagged IL-2 expression construct pcDNA-IL-2-3HA-3'UTR and miR-26a expression vec-
tor (lane 2) or control vector (lane 3) using anti-HA tag antibody. (d) Western blot analysis of the IL-2 levels in the presence of anti-miR-26a or anti-
miRNA control with anti-HA tag antibody. The levels of α-tubulin in the cell lysates are also shown as the loading control. Quantitation of the band 
densities was carried out using ImageQuant 300 software.
c
d
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in regulating miR-26a expression [4,30,31] and the altered 
expression of miR-26a in HP45 could be related to the 
increased c-myc expression. Similarly, the reduced 
expression of miR-26a in AVOL1 and AVOL2 cell lines 
may also be mediated by the v-rel. In MD tumour cell 
lines, the MDV-encoded oncoprotein MEQ is thought to 
be the primary determinant of transformation [32]. Pres-
ence of a putative MEQ-binding sequence ACACA at -
650 nucleotide position would suggest a role of MEQ in 
modulating the miR-26a expression, although further 
studies are required validate this.
Conclusions
In summary, we show that miR-26a is globally downregu-
lated in a number of avian lymphoma cells transformed 
by different oncogenic viruses that use multiple pathways 
for inducing transformation. In addition to its role as a 
global tumor suppressor miRNA, we also provide data to 
show that chicken IL-2 is a direct target for miR-26a. Our 
study suggests that the suppression of miR-26a could 
potentially relieve the inhibitory effect on IL-2 expression 
and could contribute to the proliferative features of the 
transformed lymphocyte lines.
Methods
Analysis of miRNA expression
Details of the microarray experiments carried out using 
small RNA samples prepared from transformed lympho-
blastoid cell lines, normal splenocytes were labelled with 
either Cy3 or Cy5 197 dyes using the Array 
900microRNA RT kit from Genisphere (Hatfield, PA) and 
hybridized to μRNA microarray have been described 
[33]. For Northern blot analysis, 20 μg of total RNA 
extracted from cultured cells by using TRIzol reagent 
(Invitrogen) were resolved on a 15% polyacrylamide urea 
gel and blotted onto a GeneScreen Plus membrane (Per-
kin-Elmer). DNA oligonucleotide with the complemen-
tary sequence to miR-26a was end labelled with [γ-32P] 
ATP by T4 polynucleotide kinase (New England Biolabs). 
Hybridization and autoradiography were carried out 
using standard methods as previously described [34].
Construction of reporter vectors
The region containing the IL-2 3'UTR, amplified from 
chicken spleen genomic DNA by PCR using the forward 
primer (5'-CTCGAGGCAACTAATCATTTTTATTT-
TAC TGC-3') and the reverse primer (5'-CATATAT-
TACTGAAATTTATTAAATG-3'), was cloned initially 
into pGEM-T Easy vector (Promega). The IL-2 3' UTR 
mutant with three nucleotides altered in seed sequence 
was constructed using the Quikchange™ site-directed 
mutagenesis kit (Stratagene CA) using the forward 
primer (5'-CTGCATGGACCTAACATTCGATGAT-
CATTCAGTTTAATAGG TTAAACTGCAATTGA-3') 
and reverse primer (5' TCAATTGCAGTTTAACCTAT 
TAAACTGAATGATCATCGAATGTTAGGTCCATG-
CAG-3'). After confirming the sequence of the wild type 
and mutant regions of the IL-2 3'UTR, these were cloned 
downstream of the Renilla luciferase gene through the 
NotI - XhoI site in psiCheck-2 vector (Promega) to gener-
ate psiCheck2-IL-2 3' UTR-Wt and psiCheck2-IL-2 3' 
UTR-Mu reporter constructs.
Construction of miR-26a expression vectors
For the construction of gga-miR-26a expression plasmids, 
the miR-26a primary gene together with ~200-bp flank-
ing sequences were amplified from chicken genomic 
DNA using primer pairs (5'-ATGTTCTTTAATGTCGG-
GAGC-3') and (5'-AAAGAATTCTGCCCGTGAC-3'), 
and cloned into pEF6-V5/His TOPO vector (Invitrogen) 
under control of EF1α promoter vector. Another con-
struct where the sequence was cloned in the reverse ori-
entation was used as the negative control.
Construction of chicken IL-2 expression vectors
As we did not have the specific antibodies that detect the 
chicken IL-2, we constructed IL-2 expression vector with 
a C-terminal HA tag and the 3'UTR. For this, the IL-2 
gene, amplified by PCR with the forward primer (5'-
AAGCTTGCCACCAT GATGTGCAAAGTACTGATC-
3') that included the Kozak sequence and HindIII site and 
reverse primer (5'-CTCGAGTTAAGCGTAATCTG-
GAACATCGTAT GGGTATGCCATTTTTTGCAGA-
TATCTCAC-3') carrying the haemagglutinin (HA) tag 
sequence and XhoI site, was initially cloned into pGEM-T 
Easy vector. The IL-2 gene and 3'UTR regions were 
ligated by XhoI and NotI and cloned into HindIII- NotI 
site in pcDNA3.1 vector to construct the IL-2 expression 
vector with the C-terminal HA tag and the 3' UTR.
Cell culture, reporter assays and miRNA expression
MDV-transformed lymphoid cell lines MSB-1, 226S, 
265L and 273S, avian leukosis virus (ALV)-transformed 
cell line HP45, and reticuloendotheliosis virus (REV)-
transformed cell lines AVOL1 and AVOL2 have been 
described [3]. Chicken embryo fibroblast cell line DF-1 
[35] was used for reporter assays and expression studies. 
The transfection of DF-1 cells was carried out with Lipo-
fectamine 2000 (Invitrogen) as per manufacturer's proto-
cols. Approximately 5 × 104 DF-1 cells were seeded in 
each well of a 96-well plate. Purified DNA (100 nano-
grams) of the reporter vectors were transfected into DF-1 
cells in triplicates and luciferase assay was performed 
using the Dual Glo Luciferase Assay System (Promega) 
24-hour after transfection. The relative expression levels 
were calculated as a ratio of the target specific Renilla 
luciferase to the levels the Firefly luciferase. For the 
expression of miR-26a, DF-1 cells (0.5 × 106 in each well) Xu et al. Cancer Cell International 2010, 10:15
http://www.cancerci.com/content/10/1/15
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of 6-well plate were transfected with 2 μg of the expres-
sion constructs. For silencing miR-26a expression, 5 nM 
of anti-gga-miR-26a or Cy-3-labelled control anti-
miRNA were transfected into DF-1, and analysed by 
Northern blot 48 hours later.
Analysis of IL-2 expression
Approximately 2 μg each of the purified DNA of the IL-2 
expression vectors were transfected into each well of DF-
1 cells in a 6-well plate and cell lysates collected 48 hours 
later for western blot analysis. For functional analysis of 
miR-26a-mediated silencing, IL-2 (500 ng) and miR-26a 
(2 μg) expression vectors were co-transfected into DF-1 
cells. In addition, DF-1 cells co-transfected with 5 nM 
each of anti-gga-miR-26a or Cy-3 labelled control anti-
miRNA (Ambion) with miR-26a expression or control 
vectors were also used in these studies.
For western blot analysis, cells lysates in protein gel sam-
ple buffer (8 M urea, 2% sodium dodecyl sulfate, 10 mM 
Tris-HCl [pH 6.8], 0.05% bromophenol blue) and sepa-
rated on a NuPAGE 4-12% bis-Tris gel (Invitrogen) and 
transferred onto nitrocellulose membranes using an iBlot 
gel transfer system (Invitrogen). Specific detection of IL-2 
was carried out using mouse HA.11 monoclonal antibody 
(Covance) and rabbit anti-mouse IgG peroxidase conju-
gate (Dako). The alpha-tubulin levels detected with the 
specific monoclonal antibody was used as the loading 
control. Membranes were developed with an ECL West-
ern blotting system (Amersham) and images quantified 
using ImageQuant 300 software (GE Healthcare).
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